Notably, P(AD) was consistently higher in Aβ, tau, and FDG PET positive groups, demonstrating that our framework’s diagnostic process aligns well with the current amyloid, tau, and neurodegeneration (ATN) criteria for AD diagnosis53. The gene discussed is MAPT; the disease is Alzheimer disease.